PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced that CEO Dr. Frank Bedu-Addo will present at H.C. Wainwright’s BioConnect virtual conference. The presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET. PDS Biotech is focused on developing innovative immunotherapy treatments and vaccines utilizing its proprietary Versamune® technology, which aims to enhance the immune system's ability to recognize and destroy disease cells. A replay will be accessible in the investor relations section of the company's website.

Positive

• CEO Dr. Frank Bedu-Addo will present at a significant virtual conference, indicating ongoing investor engagement.
• PDS Biotech's innovative Versamune® technology continues to develop promising cancer therapies and infectious disease vaccines.

Negative

• None.

FLORHAM PARK, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Chief Executive Officer Dr. Frank Bedu-Addo will be presenting at H.C. Wainwright’s BioConnect virtual conference. PDS Biotech’s presentation will be available on-demand beginning January 11, 2021 at 6:00 AM ET and can be accessed online here.

A replay of the presentation will be available online in the investor relations section of the Company’s website.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: jacob@cg.capital

FAQ

What is the date and time of PDS Biotechnology's presentation at the BioConnect virtual conference?

PDS Biotechnology's presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET.

Where can I access PDS Biotechnology's presentation from the BioConnect conference?

The presentation can be accessed online on-demand and will also be available in the investor relations section of PDS Biotech's website.

What technology does PDS Biotechnology utilize in its therapies?

PDS Biotechnology utilizes its proprietary Versamune® T-cell activating technology to develop cancer immunotherapies and vaccines.

Who is presenting on behalf of PDS Biotechnology at the BioConnect conference?

CEO Dr. Frank Bedu-Addo will be presenting at the BioConnect virtual conference.